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Abstract The Brassica pollen allergen Bra r 1 belongs to a new
family of Ca2+-binding proteins, characterized by the presence of
two potential EF-hand calcium-binding domains. Disruption of
these EF-hand motifs by amino acid substitutions demonstrated
that both domains of Bra r 1 constitute functional Ca2+-binding
sites. Calcium-binding deficient mutants displayed significantly
reduced IgE-binding activity. Injection of these mutated Bra r 1
variants into a murine model system showed that mouse IgG
raised against the mutants recognized native Bra r 1 in Brassica
pollen extracts suggesting the potential use of the engineered
allergens for effective immunotherapy.
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1. Introduction
Up to 20% of the human population in developed countries
su¡er from IgE-mediated atopic diseases such as allergic rhi-
nitis, conjunctivitis and bronchial asthma. Pollen from trees,
weeds, grasses and other plants represents the major airborne
cause of these allergic disorders. Diagnosis and treatment of
allergic patients require the production of large amounts of
pure and well de¢ned allergens. Recombinant DNA technol-
ogy has proven to be a useful tool for the isolation and char-
acterization allergenic proteins. Many cDNA clones encoding
major and minor pollen allergens have been isolated from
several plant species and recombinant proteins have been
used for determination of epitopes, diagnosis and immuno-
therapy [1^5].
Pollen allergens have been classi¢ed into di¡erent groups
according to sequence homologies and immunological proper-
ties [6]. Recently, a novel class of Ca2-binding pollen aller-
gens has been identi¢ed in such diverse plant species as Bras-
sica rapa Bra r 1 [7] ; Bermuda grass Cyn d 7 [8,9] ; birch Bet v
4 [10,11]; and olive Ole e 3 [12]. This group of proteins is
characterized by the presence of two potential Ca2-binding
sites of the EF-hand type. Members of this class of allergens
are small, water soluble proteins of about 9 kDa that share
signi¢cant sequence similarities extending outside the Ca2-
binding domains. Furthermore, it has been shown that Bra
r 1, Cyn d 7 and Bet v 4 share signi¢cant IgE cross-reactivities
[8,9] and must thus be considered as relevant cross-reactive
plant allergens.
With the aim to develop an allergen-speci¢c immunother-
apy, some studies have been carried out to design mutant
allergens which display low/no IgE-binding activity, but still
retain T cell epitopes and thus T cell activating capacity, as
demonstrated for the major house dust mite allergen [13,14].
Such molecules would be of signi¢cant importance for novel
approaches in immunotherapy, since they substantially de-
crease the risk of IgE-mediated anaphylactic side e¡ects. En-
gineering and precise characterization of mutant proteins with
reduced IgE-binding activity is a prerequisite for future appli-
cation in immunotherapy.
In this report, we characterized native Bra r 1 in Brassica
pollen extracts and investigated the e¡ect of protein-bound
calcium on IgE binding properties of recombinant Bra r 1.
We also generated point mutations in the ¢rst, and the second
EF-hand motifs individually and in both motifs together
which led to disruption of the Ca2-binding domains. These
Bra r 1 mutants showed signi¢cantly reduced IgE-binding
capacities. To evaluate the potential use of Bra r 1 mutants
for speci¢c immunotherapy, mutant proteins were injected
into mice and antisera were analyzed for IgG reactivity to
native Bra r 1.
2. Material and methods
2.1. Plant materials and protein extracts
Brassica rapa L. plants were grown under greenhouse conditions
and pollen grains were collected. Pollen extracellular protein was ex-
tracted as described in Evans et al. [15]. Mature pollen grains of B.
rapa were delipidated with cold acetone. Extracellular proteins were
extracted by vigorously vortexing for 10 min in 0.1 M Tris-HCl (pH
8.0) bu¡er. The supernatants were collected and used for immunoblot
analysis.
2.2. Construction of expression plasmid for mutated Bra r 1
Internal amino acid substitutions in two calcium-binding sites
were engineered by using a QuikChange Site-Directed Mutagenesis
Kit (Stratagene). Oligonucleotide primers to construct Bra r 1 mutants
by PCR are listed as follows: primer 1: TTGACACTGCC-
GGCGCTGCTAAAATATCAGC; primer 2: GCTGATATTTTAG-
CAGCGCCGGCAGTGTCAA; primer 3: GATACTGATGGTGC-
TGCAAACAAATCGTTTCAGG; and primer 4: CCTGAAACGA-
TTTGTTTGCAGCACCATCAGTATC. Bases exchanged are under-
lined. The wild-type Bra r 1 cDNA clone in pBluescript II SK3 [7]
was used as a template. Primers 1 and 2 were used for destruction of
EF-hand 1 of Bra r 1 by replacing Asp16, Asp18 and Gly19 by Ala
(mu1), and primers 3 and 4 for EF-hand 2 by replacing Asp53 by Ala,
Gly54 by Ala and Ile56 by Lys (mu2). Residues are numbered from the
¢rst Met of Bra r 1. The sequences of the mutated clones were con-
¢rmed. Wild-type Bra r 1 (WT), mu1 and mu2 were excised from
pBluescript II SK3 with BamHI and SacI and subcloned in the ex-
pression plasmid, pQE-30 (Qiagen). The double mutant (muW), which
contained two defective EF-hands, was constructed by replacing the
EF-hand 1 region of mu2 with the mutated EF-hand 1 of mu1.
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2.3. Expression and puri¢cation of recombinant Bra r 1
Wild-type Bra r 1 and the three mutants cloned into the expression
vector pQE-30 were introduced into E. coli M15 cells. Expression of
recombinant proteins was induced by addition of isopropyl-L-D-thio-
galactopyranoside, and cells were harvested after 5 h of induction.
According to the manufacturer’s instructions (Qiagen), recombinant
proteins were puri¢ed by nickel-nitrilotriacetic acid metal a⁄nity
under denaturing conditions, using urea bu¡er. The denatured pro-
teins were refolded by dialysis against PBS bu¡er (137 mM NaCl, 8.1
mM Na2HPO4, 2.68 mM KCl, 1.47 mM KH2PO4, pH 7.4) and pro-
tein concentrations were determined using the Bio-Rad assay (Bio-
Rad, CA, USA).
2.4. 45Ca2 + overlay assay
[45Ca]Cl2 (5^50 mCi/mg Ca2) was purchased from Amersham.
Equal amounts of recombinant proteins of Bra r 1 variants were
separated by electrophoresis on 15% SDS-polyacrylamide gels. After
electrophoretic transfer to PVDF membranes (PVDF-Plus; Micron
Separations), blots were washed with the bu¡er (60 mM KCl, 5 mM
MgCl2, 10 mM imidazole, pH 6.8), and then overlaid with the same
bu¡er containing 1 WCi/ml [45Ca]Cl2 (1.31 WM CaCl2) for 10 min.
Subsequently, the blot was washed with distilled water and 50%
ethanol, air-dried, and autoradiographed as described [16].
2.5. Antibody production
Antibodies against entire recombinant Bra r 1 (anti-rBra r 1) were
raised in mice. An expression plasmid was constructed by inserting
Bra r 1 cDNA into PinPoint Xa-3 vector as previously reported [7].
Recombinant fusion protein of Bra r 1 was expressed in E. coli XL-1
blue and puri¢ed using PinPoint Protein Puri¢cation System (Prom-
ega). Bra r 1 fusion proteins were injected with complete Freund’s
adjuvant (Difco) intraperitoneally into BALB/c mice and antiserum
was collected. Antiserum was puri¢ed to obtein anti-rBra r 1 speci¢c
IgG as described in Lin et al. [17]. The speci¢city of anti-rBra r 1
antiserum was tested by immunoblot analysis, using pollen extracts of
B. rapa.
Antisera against recombinant mutant Bra r 1s were prepared by
injecting a⁄nity-puri¢ed mutant proteins (30^50 Wg) with complete
and incomplete Freund’s adjuvant (Sigma) subcutaneously into
BALB/c mice at intervals of two weeks. Blood samples were taken
one week after the immunizations and production of speci¢c IgG
antibodies against mutant proteins was con¢rmed by immunoblot
analysis.
To obtain anti-peptide antiserum (anti-C-pep), a peptide of 15 ami-
no acids corresponding to the C-terminal region of Bra r 1
(ASANPGLMKDVAKVF) was synthesized and injected into rabbits
(Sawady technology). Antiserum was collected and used for immuno-
blot and ELISA assay.
2.6. Immunoblot analysis
Recombinant proteins and Brassica pollen extracts were separated
by SDS-PAGE (15% polyacrylamide gel) or thin-layer polyacrylamide
gel isoelectric focusing (IEF; pI 3.5^9.5, Pharmacia). After electro-
phoresis, proteins were electroblotted onto PVDF membranes
(PVDF-Plus, Micron Separations; and Immobilon, Millipore). The
blots were probed with mouse anti-rBra r 1, rabbit anti-C-pep or
sera from allergic individuals. After washing with TBS or PBS bu¡er
containing 0.05% Tween-20, the blots were incubated with secondary
antibody, alkaline phosphatase (AP)-conjugated anti-mouse IgG
(Promega), AP-conjugated anti-rabbit IgG (Promega), AP-conjugated
anti-human IgE antibodies (Sigma), or peroxidase-conjugated anti-
human IgE (KPL). After washing, the signal was visualized by incu-
bation with 5-bromo-4-chloro-3-indolyl-phosphate p-toluidine salt
and nitroblue tetrazolium chloride solution for AP or using enhanced
chemiluminescence for peroxidase according to the ECL Western
Blotting Analysis System (Amersham).
2.7. ELISA
Antibody binding capacity of recombinant Bra r 1 (rBra r 1) was
determined by ELISA. ELISA and inhibition ELISA were performed
as previously described [18]. Microtiter plates (Greiner Labortech)
were coated with 50 ng/well rBra r 1. The bound antigen was washed
with PBS containing 0.05% Tween-20 (PBST) and the free sites were
blocked with 1% BSA in PBST. Subsequently plates were incubated
overnight with either 1:10 diluted human sera, 1:500 diluted mouse
anti-rBra r 1 or 1:10 000 diluted rabbit anti-C-pep in 1% BSA in PBS
at 4‡C. After washing with PBST, the plates were incubated with
1:4000 diluted AP-conjugated anti-human IgE (Sigma), 1:7500 di-
luted AP-conjugated anti-mouse IgG (Promega), or 1:5000 diluted
AP-conjugated anti-rabbit IgG (Promega) at room temperature. After
washing, ELISA substrate (KPL) was added. The reaction was
stopped by addition of 2.5% EDTA and optical density was measured
at 630 nm, using a plate reader (Packard). For ELISA inhibition
analysis, primary antibodies were preincubated with di¡erent concen-
trations of Bra r 1 variants (10^1000 ng/ml). The percentage of inhib-
ition was calculated using the following formula: inhibition
(%) = 100U[(A3B)/A], where A represents absorbance without the
inhibitor and B absorbance with inhibitor. Triplicate assays were per-
formed for each dilution and average values are displayed.
3. Results
3.1. IgE reactivity of Bra r 1
Bra r 1 has been isolated as a cDNA clone encoding a
pollen allergen of Brassica rapa by IgE-immunoscreening of
an anther cDNA expression library [7]. However, Bra r 1
protein has not yet been identi¢ed in Brassica pollen extracts.
In order to identify Bra r 1 among the proteins present in a
pollen extract with patient’s serum, the following competition
experiment was carried out: rBra r 1 produced in E. coli M15
as a fusion protein with a histidine tag at the N-terminus, was
a⁄nity puri¢ed and used for depletion of antibodies speci¢c
to Bra r 1. The serum used in this study reacted with several
proteins in an IEF-gel blot of extracellular Brassica pollen
proteins (Fig. 1, lane 1). Preincubation of the serum with
rBra r 1 revealed loss of a band at pI 4.34 (Fig. 1, lane 2;
arrow head), indicating that the band at pI 4.34 represents
Bra r 1 protein. This pI value coincides with that predicted
from the cDNA sequence of Bra r 1.
For further analysis of Bra r 1 protein, a mouse antibody
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Fig. 1. Identi¢cation of a Brassica pollen allergen encoded by Bra r
1. Soluble pollen extract of B. rapa was separated by IEF and the
blots were probed with patient’s serum (lane 1), or patient’s serum
preincubated with rBra r 1 (lane 2). IgE binding was detected by
ECL. The membrane strip shown in lane 2 was reprobed with
mouse speci¢c antibody against rBra r 1 (lane 3). Arrow head repre-
sents the position of Bra r 1. Circles indicate the position of sample
application on a piece of ¢lter paper and do not indicate the sig-
nals.
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was raised against rBra r 1. In an IEF-gel blot of extracellular
pollen proteins mouse anti-rBra r 1 antibody reacted with a
single band at pI 4.34. This result corresponded with the data
obtained in the depletion experiment of human IgE (Fig. 1,
lane 3). Thus, it is clear that among the proteins present in a
pollen extract mouse anti-rBra r 1 antibody speci¢cally re-
acted with Bra r 1 exclusively.
3.2. E¡ect of Ca2+ on IgE reactivity
As a next step we investigated the in£uence of protein
bound calcium on IgE recognition of rBra r 1 by depleting
calcium binding with EGTA. First, sera of 80 pollen allergic
patients were tested for their IgE reactivity to rBra r 1 and
among them the two sera (KT and KS) that showed strongest
reactivity were chosen for the described depletion experi-
ments.
When SDS-gel blots of rBra r 1 were incubated with serum
KT, KT IgE bound rBra r 1 in the presence of EGTA with
the same intensity as in the absence of EGTA (Fig. 2). This
result was also con¢rmed in ELISA experiments and it was
concluded that IgE-recognition of rBra r 1 by KT serum was
not in£uenced by calcium depletion. On the other hand, IgE
binding of serum KS was greatly reduced by EGTA treatment
(Fig. 2). Quantitative analysis using ELISA assays revealed a
reduction of 84%. These data show that the e¡ect of depletion
of protein-bound calcium with EGTA varies among patients.
Serum IgE from a non-allergic patient did not bind to rBra r 1
in the presence or absence of EGTA (Fig. 2).
We further tested the e¡ect of calcium depletion on the
binding of mouse anti-rBra r 1 IgG and rabbit anti-C-pep
IgG. In the case of anti-rBra r 1 IgG, depletion of calcium
with EGTA showed a substantial reduction of binding to rBra
r 1 (Fig. 2), as observed in the case of serum KS. When SDS-
gel blots were incubated with anti-C-pep IgG, rBra r 1 was
detected equally in the presence or in the absence of EGTA,
indicating that removing Ca2 had no e¡ect on the structure
of the C-terminal epitope of rBra r 1 (Fig. 2).
3.3. Calcium binding ability of Bra r 1 mutants
To evaluate whether both EF-hand domains are able to
bind calcium, we introduced point mutations in each domain.
The introduced mutations are summarized in Fig. 3. Mu1
contains three point mutations in domain 1, mu2 contains
three point mutations in domain 2, and muW contains both
mutated domains. Each recombinant protein was expressed in
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Fig. 2. E¡ect of protein-bound Ca2 on antibody binding of rBra r
1. Recombinant wild-type Bra r 1 was separated by SDS-PAGE,
blotted onto PVDF membranes and tested for antibody reactivity
using sera from pollen allergic patients (KT and KS), serum from a
non-allergic individual, rabbit antiserum against a C-terminal poly-
peptide (anti-C-pep) of Bra r 1, and mouse anti-rBra r 1 antiserum
(anti-rBra r 1). Blocking, incubation of primary antibody and wash-
ing procedures were carried out either in the presence (+) or ab-
sence (3) of 5 mM EGTA. Microtiter plates were coated with rBra
r 1 and ELISA assays were performed in the same manner as men-
tioned above. The percentage of IgE- or IgG-binding activity ob-
served in the absence of EGTA as compared to the reactivity ob-
tained in the presence of EGTA, is given under the immunoblots.
Fig. 3. Schematic representation of the structure of Bra r 1 mutants.
Hatched boxes and shaded boxes represent histidine tags and EF-
hand motifs, respectively. Amino acid sequences of EF-hand do-
mains are given below the structures. Cross marks in the EF-hand
domains indicate the positions of the point mutations. WT: wild-
type Bra r 1 fused with histidine tag; mu1: Bra r 1 mutated in EF-
hand 1; mu2: mutation in EF-hand 2; muW: mutation in both EF-
hands. BamHI and ClaI sites used to construct the double mutant
are indicated as B and C, respectively.
Fig. 4. Calcium-binding ability and immunoblot analysis of Bra r 1 mutants. A⁄nity-puri¢ed recombinant proteins of wild-type Bra r 1 (WT)
and three Ca2-binding de¢cient mutants of Bra r 1 (mu1, mu2 and muW) were separated by SDS-PAGE. A: Coomassie Blue-stained gel. B:
An autoradiogram of a blot overlaid with [45Ca]Cl2 solution. Protein blots were probed with sera from patient KT (C) and rabbit anti-C-pep
(D). Molecular weight markers are indicated on the left in A.
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E. coli as a fusion protein with an N-terminal histidine tag,
puri¢ed and analyzed by SDS-PAGE.
Coomassie Brilliant Blue staining of an SDS-gel showed
that each recombinant protein was properly expressed with
the expected molecular size of 9 kDa (Fig. 4A), and con¢rmed
that equal amounts of proteins were loaded. 45Ca2 overlay
assay showed a strong signal in wild-type Bra r 1 (Fig. 4B).
The mutants, mu1 and mu2, each containing one intact cal-
cium-binding domain, clearly bound calcium, although the
signal was approximately 50% of that of wild-type Bra r 1
(Fig. 4B). The double mutant, muW, which had both calcium-
binding sites disrupted, showed a complete loss of calcium-
binding activity (Fig. 4B). These results indicate that both
domains have the ability to bind calcium and that site-directed
mutagenesis successfully abolished the calcium-binding ability
of each domain.
3.4. Reactivities of IgE to Bra r 1 mutants
IgE-binding capacity of recombinant mutant Bra r 1s was
determined by ELISA inhibition analysis. Patients’ sera pre-
incubated with di¡erent amounts of rBra r 1 variants were
added to ELISA plate wells coated with wild-type rBra r 1.
The ability of the mutant proteins to inhibit binding of IgE
to rBra r 1 was shown as percent inhibition in Fig. 5. In the
case of KT serum, wild-type Bra r 1 gave 94% inhibition, mu1
79%, mu2 50%, and muW 19% at the highest inhibitor con-
centrations tested (1000 ng/ml). In the case of KS serum,
percent inhibition of IgE binding was remarkably lower in
mu1, mu2 and muW than in the wild type. At the highest
concentration of inhibitors (1000 ng/ml), 74% inhibition was
observed with wild-type Bra r 1, 23% with mu1, 16% with
mu2, and 13% with muW. These results indicate that KT
and KS IgE antibodies have reduced a⁄nity to Bra r 1 mu-
tants, especially domain 2 mutant and the double mutant as
compared to the wild-type protein. Mouse IgGs showed pro-
¢les of percent inhibition similar to that of KS IgEs (Fig. 5C).
These results indicate that mutations in either EF-hand do-
main signi¢cantly reduce IgE- and IgG-binding ability. How-
ever, mutation of domain 2 is more e¡ective than mutation of
domain 1 in reducing IgE and IgG binding.
The ability of the Bra r 1 mutants to interact with IgE was
also examined by SDS-gel blot analysis. IgE from patient KT
reacted with mu1 and mu2, but the signals were much weaker
than the signal obtained with wild-type Bra r 1 protein and
mu2 bound signi¢cantly less IgE than mu1 (Fig. 4C). These
data are consistent with the results obtained in ELISA inhib-
ition assays. Furthermore, KT serum did not react with muW.
Thus, it was concluded that disruption of both Ca2-binding
sites completely abolished IgE binding. The same SDS-blot
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Fig. 5. Inhibition of antibody binding to immobilized rBra r 1 using Bra r 1 variants. Antibody binding to rBra r 1 was inhibited by preincu-
bation of sera from patient KT (A), patient KS (B), and anti-rBra r 1 (C) with increasing concentration of wild-type Bra r 1 (¢lled square),
mu1 (open square), mu2 (¢lled circle) and muW (open circle).
Fig. 6. Immunoblot analysis of recombinant Bra r 1 (A) and Brassi-
ca pollen extracts (B). Recombinant Bra r 1 and pollen extracts
were separated by SDS-PAGE and IEF, respectively, and blotted
onto PVDF membranes. Membrane strips were incubated with
mouse preimmue serum (lane 1), anti-rBra r 1 (lane 2), anti-mu1
(lane 3), anti-mu2 (lane 4) or anti-muW (lane 5) antisera. Binding
IgG was detected by color development. Arrow heads indicate the
position of Bra r 1.
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was also incubated with anti-C-pep antibody, and identical
intensity of bands was observed in case of wild-type Bra r 1
and the mutated proteins (Fig. 4D), indicating that the C-
terminal epitope was not a¡ected by disruption of the calci-
um-binding sites.
3.5. Mouse IgG raised against Bra r 1 mutants recognized
native Bra r 1
To evaluate the application of Bra r 1 mutants for allergen-
speci¢c immunotherapy, we obtained mouse antisera raised
against the mutant proteins mu1, mu2 and muW. The pro-
duction of speci¢c IgG against the respective mutants was
con¢rmed by SDS-gel blot analysis (data not shown). As
shown in Fig. 6A, sera raised against Bra r 1 mutants were
still able to react with rBra r 1. Furthermore, each serum also
recognized native Bra r 1, as shown in the IEF-gel blot of
Brassica pollen extract (Fig. 6B).
4. Discussion
Bra r 1 was initially isolated as a cDNA clone encoding a
two EF-hand Ca2-binding pollen allergen by immunoscreen-
ing of a Brassica pollen expression library with patient’s se-
rum [7]. Bra r 1 has an expected small molecular mass of 8.9
kDa and a pI value of 4.35. By using an antibody directed
against rBra r 1 we identi¢ed Bra r 1 protein in a Brassica
pollen extract with the expected pI value (Fig. 1).
Homologous two EF-hand calcium-binding pollen allergens
with similar molecular mass and pI value have been reported
as Ole 3 from olive [12], Bet v 4 from birch [10,11] and Cyn d
7 from Bermuda grass [8,9]. The close similarity of these al-
lergens of very distantly related plant species indicates that
they might represent a group of highly conserved pollen aller-
gens. In addition, IgE cross-reactivity that has been observed
between Bet v 4, Cyn d 7 and Bra r 1 [9^11] further suggests
that this group of Ca2-binding proteins must be considered
as important cross-reactive plant allergens.
Calcium-binding proteins are known to change their con-
formations in the presence or absence of Ca2 [19^21]. Experi-
ments using EGTA to deplete protein bound calcium indi-
cated that the in£uence of calcium binding on IgE reactivity
towards Bra r 1 varied among patients (Fig. 2). Previous
studies showed that IgE recognition of Cyn d 7, Bet v 4
and Bet v 3, a Ca2-binding pollen allergen with three EF-
hand domains, required protein-bound calcium [8,9,11,22].
However, recently Engel et al. [10] reported that two out of
¢ve patients’ sera did not need calcium for IgE recognition of
Bet v 4. Similar results have been reported for parvalbumin, a
12-kDa Ca2-binding protein, which has been characterized as
the major ¢sh allergen where depletion of Ca2 led to a re-
duction of IgE binding in some patients [23^25]. However, in
the case of other patients depletion of Ca2 did not have an
e¡ect on IgE reactivity [25].
In our study, in vitro mutagenesis experiments demon-
strated that both EF-hand domains constitute functional
Ca2-binding sites (Fig. 4B), since mutations introduced in
mu1 and mu2 abolished the binding of calcium (Fig. 4B).
Furthermore, we could show that disruption of the two cal-
cium-binding sites resulted in decreased IgE binding to Bra r 1
for both sera tested (Fig. 5B). For KS serum, the observed
IgE reactivity patterns were consistent with those obtained
upon depletion of protein-bound calcium by EGTA. It was
therefore concluded that mutations in the EF-hand domains
led to conformational changes in discontinuous IgE epitopes
substantial for KS IgE binding (Fig. 2). In addition, it seems
that certain amino acids of the EF-hands are also part of
continous (linear) IgE epitopes, recognized by IgE antibodies
of KT serum. These epitopes are not a¡ected by Ca2 remov-
al mediated local conformational changes. Nevertheless, these
linear epitopes also seem to be destroyed by amino acid sub-
stitutions, since KT IgE binding reactivity is signi¢cantly re-
duced with Bra r 1 mutants.
Furthermore, we also demonstrated that mutations in do-
main 2 were more e¡ective in reducing IgE reactivity than
changes in domain 1 (Fig. 5). This also seems to be true for
other members of the calcium-binding pollen allergen class.
Mutagenesis analysis of Bet v 4, the Bra r 1 homologue from
birch, for instance, revealed that most Bet v 4-speci¢c IgE
antibodies were directed to the second calcium-binding do-
main. In case of Cyn d 7, the homologous allergen from
Bermuda grass, a synthetic peptide of EF-hand domain 2
completely inhibited IgE binding to recombinant Cyn d 7,
whereas a peptide of domain 1 could not lead to a decrease
in IgE reactivity [8].
Treatment of allergic diseases is performed as allergen-spe-
ci¢c immunotherapy, where increasing doses of allergens are
injected for successful immunotherapy. However, the risk of
anaphylactic reaction increases as well. To solve this problem,
low IgE-binding forms of allergens would represent useful
tools, since they have a reduced risk of such adverse reactions.
Recently, hypoallergenic forms of allergens of mite Der f 2
and birch pollen Bet v 1 engineered by site-directed mutagen-
esis displayed reduced IgE-binding activity but still retained T
cell epitopes essential for immunotherapy [14,26].
Recently, vaccination of mice with a multi-epitopic re-
combinant allergen of grass pollen suppressed an IgE anti-
body response but showed an increase in speci¢c IgG in a
dose-dependent manner [27]. After preincubation of Bet v 1
with a mouse monoclonal antibody, directed against the aller-
gen, histamine release could be inhibited [28]. Furthermore,
preincubation with human monoclonal antibodies against Bet
v I inhibited IgE binding as well as histamine release [29]. It
can thus be expected in allergen-speci¢c immunotherapy that
production of allergen-speci¢c IgG antibodies might lead to a
modulation in the immune response to allergens.
In conclusion, we engineered Ca2-binding de¢cient mu-
tants of Bra r 1 which showed lower IgE reactivity than the
wild-type protein. These recombinant mutant forms of Bra r 1
were injected into mice as a model system, to examine their
potential for productive immune response. Speci¢c IgGs
against Bra r 1 mutants were produced and these IgGs could
recognize native Bra r 1 in pollen extracts as well as rBra r 1
(Fig. 6). These results strongly suggest that recombinant Bra r
1 mutants with reduced anaphylactic index could be useful
tools for allergen-speci¢c immunotherapy. Furthermore, due
to signi¢cant IgE cross-reactivity of Bra r 1 with other Ca2-
binding pollen allergens, hypoallergenic variants of Bra r 1
have also the potential to be used as ‘cross-protective’ ther-
apeutic agents for e¡ective immunotherapy against allergies to
related proteins such as Cyn d 7 and Bet v 4.
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